Cipla receives USFDA nod for acromegaly drug Lanreotide

Cipla gets USFDA nod: Cipla on Wednesday announced that it has secured approval from the US health regulator to market a generic medication primarily used in the treatment of acromegaly and other related conditions.

The Mumbai-based drug manufacturer in a regulatory filing said that it has obtained final approval from the US Food and Drug Administration (USFDA) to introduce Lanreotide injection in various strengths.

Cipla's Lanreotide Injection serves as a therapeutic equivalent generic version of Somatuline Depot Injection, offering patients a cost-effective alternative for their medical needs.

The newly approved product is indicated for treating patients diagnosed with acromegaly and gastroenteropancreatic neuroendocrine tumours, addressing critical medical requirements within these patient populations.

IQVIA (IMS Health) data indicates that Somatuline Depot, the reference drug, recorded sales of approximately $898 million in the US over the 12-month period ending March 2024, underlining the significant market potential for Cipla's Lanreotide Injection.

Following this development, Cipla shares rose 3.37 per cent to Rs 1,490, outperforming the Sensex which was up 0.2 per cent.

(With PTI inputs)